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 A B S T R A C T  Objective To evaluate a new levonorgestrel-releasing intrauterine system (LNG-IUS) 
called Levosert  ®  for the treatment of heavy menstrual bleeding (HMB) in comparison to 
the reference product Mirena  ®  . 
  Methods A multicentre, randomised, controlled trial, in non-menopausal women diag-
nosed with functional HMB (defi ned as menstrual blood loss [MBL]    80 mL) randomised 
to either Levosert  ®  or Mirena  ®  and followed for up to one year. MBL was evaluated using 
a validated modifi ed version of the Wyatt pictogram. 
  Results A total of 280 women were randomised (141 to Levosert  ®  and 139 to Mirena  ®  ). 
During the one-year treatment period, both Levosert  ®  and Mirena  ®  dramatically decreased 
MBL and increased haemoglobin and ferritin levels. There were no statistically signifi cant 
differences between Levosert  ®  and Mirena  ®  regarding any of the parameters evaluated 
during the study. Similar bleeding patterns were observed in both groups. Levosert  ®  was 
inserted with the same ease as Mirena  ®  . Both treatments were associated with identical 
expulsion rates and no perforations occurred in either treatment group. 
  Conclusion Levosert  ®  , a new LNG-IUS designed to release the same daily amount 
of LNG as Mirena  ®  , is highly effective in the treatment of HMB. No differences were 
observed between Levosert  ®  and Mirena  ®  regarding all evaluated outcomes, including safety 
profi le. 
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 I N T R O D U C T I O N  
 Heavy menstrual bleeding (HMB) affects 10 to 35% 
of women 1 – 5 . Treating this disorder may improve a 
woman ’ s quality of life and may prevent the occur-
rence of iron defi ciency anaemia. 
 ‘ Normal ’ levels of menstrual blood loss (MBL) vary 
between cycles within the same woman, with 40% 
experiencing a 10 mL difference between cycles 6 . Iron 
depletion and anaemia occur when menstrual fl ow 
regularly amounts to approximately 60 and 120 mL 
MBL, respectively 7 . HMB is classically defi ned as blood 
loss of- or exceeding 80 mL per menstrual cycle 8,9 . 
The anomaly is the consequence of a variety of 
functional, non-structural, and structural conditions. 
Among the latter the main causes are adenomyosis and 
fi broids (leiomyomata). Non-structural causes refer to 
coagulopathies and iatrogenic causes 10 . In a substantial 
proportion of women, the underlying cause of HMB 
remains unknown and is referred to as functional 
HMB 11 . 
 Whenever possible, HMB treatment should specifi -
cally target its underlying cause. A medical approach 
should be the fi rst line of treatment 12 . Surgery (endo-
metrial ablation and hysterectomy) is associated with 
perioperative and long-term surgical risks 13 , and does 
not preserve fertility. Strong evidence indicates that the 
intrauterine system (IUS), releasing controlled amounts 
of levonorgestrel (LNG), is an effective medical treat-
ment for HMB and is superior to drugs administered 
orally such as oral contraceptives, tranexamic acid and 
non-steroidal anti-infl ammatory drugs, whether used 
alone or in combination 12 – 16 . The 2005 Cochrane 
meta-analysis identifi ed ten randomised controlled tri-
als (RCTs) comparing the LNG-IUS with surgery or 
various oral HMB treatments. The calculated odds 
ratio (OR) for amenorrhoea was 8.67 (95% confi -
dence interval [CI]: 1.52 – 49.35) favouring treatment 
with a LNG-IUS 16 . 
 The LNG-IUS Mirena  ®  (Bayer Healthcare 
Pharmaceuticals, Germany) was approved for the 
treatment of HMB more than a decade ago in 
Europe; the US Food and Drug Administration 
approved the system for this indication in 2009. 
 In the present study, the effectiveness for treatment 
of functional HMB of a new LNG-IUS, called 
Levosert  ®  (Uteron Pharma Sprl, Li è ge, Belgium), 
was compared with the reference IUS Mirena  ®  , during 
one year of use. Like Mirena  ®  , Levosert  ®  contains 
 Figure 1 Levosert  â  and its inserter are depicted in picture 
(A) and in insert a, respectively. Mirena  â  and its inserter 
are shown in picture (B) and in insert b, respectively. 
52 mg of LNG in a cylindrical-shaped reservoir 
mounted on the vertical arm of a T-shaped plastic 
frame. The reservoir is covered with a membrane con-
trolling the release rate of the progestin, so as to deliver 
 in utero the same daily amount of LNG as does Mirena  ®  . 
Although minute structural differences exist between 
Mirena  ®  and Levosert  ®  (different shapes of horizontal 
extremities, thinner plastic vertical arm [Levosert  ®  
1.2 mm, Mirena  ®  1.5 mm], and smaller inferior loop), 
the most signifi cant difference pertains to its mode of 
insertion. Whereas Mirena  ®  is fi tted by means of a 
specifi c one-handed inserter, the one used for placing 
a Levosert  ®  is a two-handed cylindrical tube, similar 
to that used for the Nova-T copper intrauterine device 
(Cu-IUD). The Levosert  ®  inserter closely resembles 
the two-handed Mirena  ®  inserter commonly used in 
France. This difference may have a signifi cant impact, 
particularly in developing countries where healthcare 
professionals are more used to placing intrauterine 
devices with a two-handed inserter and where access 





























































Impact of Levosert® on heavy menstrual bleeding Mawet et al.
The European Journal of Contraception and Reproductive Health Care 3
 The development of a reliable progestin-releasing 
IUS for long-term use is complex. Despite multiple 
attempts since the 1970s, only Mirena  ®  has successfully 
completed the approval process so far. Diffi culties 
inherent to IUS development (long-term clinical 
studies, sophisticated technologies, specifi c pharmaco-
dynamics with local action only) have precluded thus 
far the launch of other IUSs. 
 Levosert  ®  development required full clinical 
investigation of its effi cacy in treating HMB and its 
contraceptive properties. The use of  in vitro release 
studies or the demonstration of similar plasma LNG 
levels between Levosert  ®  and Mirena  ®  users in 
bioequivalence studies is not suffi cient for agencies to 
consider clinical effi cacy. The local mode of action of 
the LNG-IUS and its pharmacodynamics preclude 
extrapolation of systemic data to local impact and 
clinical effi cacy. Large clinical trials were therefore 
required to demonstrate the clinical performance of 
Levosert  ®  . 
 In this study, the effect of local LNG release from 
Levosert  ®  or Mirena  ®  on the MBL is described. The 
contraceptive effi cacy will be described elsewhere. 
 M E T H O D S  
 IUS development 
 Levosert  ®  consists of four parts: a polyethylene T-frame, 
a polypropylene thread, a reservoir made of a mix-
ture of LNG and polydimethylsiloxane (PDMS), and 
a PDMS membrane that controls LNG diffusion. 
A quality by design strategy was developed according 
to the current state of the art pharmaceutical develop-
ment guidelines, i.e., ICH Q8(R2) 17 . The 21CFR part 
820.30 guideline 18 was used for the development of 
the T frame, thread and inserter. 
 The major structural differences between Levosert  ®  
and Mirena  ®  concern the T-frame: the buds at the end 
of the horizontal arms of Levosert  ®  are more fl attened 
and its vertical stem is thinner (diameter: 1.2 mm vs. 
1.5 mm for Mirena  ®  ). The loop at the end of the 
vertical stem (width: 1.8 mm vs. 2.4 mm for Mirena  ®  ) 
and the hole in it (length: 0.85 mm and width: 0.6 mm 
vs. 2.2 mm and 1.3 mm, respectively, for Mirena  ®  ) 
are both smaller. The two intrauterine systems also 
differ with regard to the composition of the thread 
which is in polypropylene dyed with phtalocyaninato 
(2-)copper for Levosert  ®  , and in polyethylene with 1% 
ferric oxide for Mirena  ®  . None of these differences 
affects the IUS ’ s performance or the ease of its 
insertion. 
 Study design 
 The study was a multicentre, randomised, parallel 
group, single-blind clinical trial. Women who met the 
inclusion- and exclusion criteria were randomised to 
either Levosert  ®  or to Mirena  ®  in a 1:1 ratio for a 
duration of up to 12 months. Twelve centres located 
in Serbia (one centre), Romania (eight centres), and 
Macedonia (three centres) took part in the trial, which 
lasted from December 2007 (initiation of recruitment) 
to January 2010 (completion of the fi nal assessment). 
It was conducted in accordance with the principles 
of the Declaration of Helsinki and the International 
Conference on Harmonization  – Good Clinical Practice 
guidelines. The study protocol was approved by the 
appropriate Ethics Committees before the study started: 
in Romania, by the National Ethics Committee for 
Clinical Study of Drugs at the Medical Sciences 
Academy; in Serbia, by the Ethics Committees of the 
Gynaecology and Obstetrics Clinic  ‘ Narodni front ’ , the 
Clinical Centre of Serbia, the Mother and Child Health 
Care Institute of Serbia and the Clinical Centre of 
Vojvodina; and, in Macedonia, by the Ethics Com-
mittee of the Faculty of Medicine in Skopje. The trial 
was registered in the Romanian National Medicinal 
Agency under EudraCT number 2007-001564-77. 
 Selection criteria 
 Women were eligible to enter the trial if they were 
at least 18 years of age, not pregnant nor planning 
to become pregnant, not lactating, not menopausal, 
and had a clinical diagnosis of functional HMB for 
at least six months prior to screening. Exclusion 
criteria were: a known or suspected pregnancy; a 
history of endometrial ablation or curettage during the 
preceding three months; use of a Cu-IUD or LNG-
IUS during the two months prior to screening; cur-
rent use of other hormonal treatment (sex steroids); 
endometrial polyps; submucous myomas of any size or 
intramural or subserous myomas greater than 3 cm; 
adenomyosis; atypical hyperplasia or carcinoma of the 
endometrium; an abnormal Pap smear test or other 
evidence of cervical malignancy; abnormal uterine mor-
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hormone-dependent tumour; lower genital tract infec-
tion; pelvic infl ammatory disease during the past three 
months; abnormal liver function; renal insuffi ciency; 
uncontrolled hypertension; valvular disease (including 
corrections with prosthetic valves); a body mass index 
(BMI)    30 kg/m 2 , and hypersensitivity to device 
material and/or LNG. 
 Women who met these criteria and who signed the 
written informed consent form were followed for 
three cycles prior to randomisation, during which 
their MBL was measured by means of the modifi ed 
Wyatt pictogram 19 . To ensure the homogeneity of the 
measurements, all women were given the same sanitary 
pads (brand: Always  ®  Ultra sensitive normal plus and 
super plus). For this trial, the pictogram and related 
digital photos used by Wyatt  et  al . were adapted to 
Always  ®  sanitary products. The usability and readabil-
ity of these modifi ed pictogram and related photos 
were validated before starting the study; validation 
involved 20 women of various ages and educational 
backgrounds. Only women with documented HMB 
(   80 mL) for at least two bleeding episodes were 
randomised in a 1:1 ratio to either Levosert  ®  or 
Mirena  ®  . Randomisation was done using a two digit 
number allocated to the subject based on the sequence 
of the woman ’ s arrival at the study site. All women 
with even randomisation numbers received Mirena  ®  , 
those with odd numbers, Levosert  ®  . 
 Interventions 
 The study included two treatment groups: the 
Levosert  ®  and the Mirena  ®  groups. Both IUSs were 
inserted within the fi rst seven days of the menstrual 
cycle, according to the manufacturer ’ s instructions. 
Participating women were to be followed for the 
12-month study period. 
 Study outcomes 
 MBL during each menstrual cycle was evaluated 
using the modifi ed Wyatt pictogram scoring system 
and recorded on a diary card. To increase the reli-
ability of the measurements, screened women were 
instructed on how to interpret the modifi ed Wyatt 
pictogram and had a chance to complete it during 
the three cycles prior to randomisation. Only, those 
who successfully completed the pictogram scoring 
were included. 
 Endometrial thickness was assessed by trans-vaginal 
ultrasonography (TVUS) at baseline, and three, ten and 
twelve months after insertion of the IUS. To this end, 
the distance between the basal layers of the endome-
trium covering the anterior and posterior uterine walls 
(at the echogenic interface between endometrium and 
myometrium) was measured. To harmonise the data 
regarding endometrial thickness across the different 
participating centres, all investigators were trained by an 
expert in gynaecological ultrasound. Effects of the treat-
ment on MBL were also indirectly assessed by the mea-
surement of haemoglobin and ferritin levels at baseline, 
and one, three, ten and twelve months after initiation of 
treatment. A urinary pregnancy test was performed at 
each visit. Adverse events, concomitant medications and 
cycle control pattern (menstrual cycle length, days of 
spotting and bleeding) were recorded in daily diaries. 
 Statistical analysis 
 For all statistical calculations SAS  ®  9.2 (SAS Institute) 
was used. Based on the magnitude of the individual 
variability in MBL reduction reported for Mirena  ® 12 
and the documented 10 mL MBL difference between 
spontaneous cycles within the same woman 6 , the limit 
for claiming the equivalence between Levosert  ®  and 
Mirena  ®  was defi ned as    20 mL in terms of MBL 
reduction. Based on a standard deviation of 48.9 mL 
for the MBL reduction (estimated by simulations 
based on the results published by Kaunitz  et  al . 12 ) and 
assuming that the true difference between Levosert  ®  
and Mirena  ®  in terms of MBL reduction would not 
exceed 5 mL, it was determined that a sample size of 
280 women (140 women in each treatment group) 
was needed. Equivalent effi cacy in terms of reduc-
tion of HMB required therefore that the 95% CI for 
the difference in MBL reduction be within    20 mL 
(SAS  ®  9.2 Proc power). 
 All safety and effi cacy endpoints were summarised by 
descriptive statistics (mean, standard deviation, standard 
error of the mean, and percentage) for continuous data 
or by frequency tables for ordinal or nominal data. 
 The two treatment groups were compared at 
baseline using an independent t-test (SAS  ®  9.2 Proc 
ttest) for age, number of deliveries, BMI, MBL, 
haemoglobin, ferritin and endometrial thickness, and 
a chi-squared test for the proportion of subjects with 
iron defi ciency anaemia defi ned by a haemoglobin 
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the end of the treatment period, changes from baseline 
were compared between both treatments for the 
following outcomes: mean blood loss, haemoglobin, 
ferritin, and endometrial thickness. The results at base-
line and at end-of-study are reported as arithmetic 
means and standard deviation. For this evaluation, a 
model of analysis of covariance (ANCOVA) was used, 
with the treatment as fi xed effect and the baseline 
value as continuous covariate (using SAS  ®  9.2 Proc 
mixed). These outcomes were primarily assessed taking 
into account the intention-to-treat (ITT) principle 
with a last-observation-carried-forward (LOCF) impu-
tation of the missing values, and secondarily using a 
per-protocol (PP) analysis without imputation of the 
missing values. To refl ect the statistical inference 
achieved, the changes from baseline are presented as 
least-squares means, i.e. means adjusted for the different 
factors included in the statistical model. The treatments 
have been statistically compared using an analysis of 
covariance (ANCOVA) with the baseline value added 
as a continuous covariate. The least-squares means on 
the change from baseline were adjusted for the effect 
due to the baseline by SAS  ®  9.2 Proc mixed. 
 R E S U L T S  
 Study population 
 A total of 341 women were screened and, of these, 
280 were randomly allocated to one of the two treat-
ment groups: 142 to the Levosert  ®  group and 138 to 
the Mirena  ®  group; they constituted the ITT popula-
tion. Of these, 126 and 121 participants completed 
the treatment year in the Levosert  ®  and the Mirena  ®  
groups, respectively. At the end of the study, 219 of 
them had no major protocol deviations and were 
includ ed in the PP population, i.e., 113 in the Levosert  ®  
group and 106 in the Mirena  ®  group. All 280 ran-
domised women were included in the safety population. 
However, due to an inversion of treatment, one woman 
randomised to Levosert  ®  actually received Mirena  ®  ; as a 
result thereof the safety population includes 141 women 
treated with Levosert  ®  and 139 treated with Mirena  ®  
(Figure 2). No statistically signifi cant differences were 
found between the baseline characteristics of the two 
groups for age, BMI, parity, MBL, haemoglobin and 
ferritin levels, endometrial thickness and incidence of 
iron defi ciency anaemia (Table 1). All subjects enrolled 
were Caucasian. 
 Menstrual blood loss 
 Table 2 displays the changes observed in MBL and 
related parameters (endometrial thickness, haemo-
globin and ferritin levels) after one year of treat-
ment. Results are compared to those obtained with 
the reference product, Mirena  ®  , in both ITT and PP 
populations. 
 Levosert  ®  - as well as Mirena  ®  users experienced a 
consequent and similar ( p   0.1) reduction in MBL 
(   142.3 and    146.4 mL, respectively, in the ITT 
population;    150.9 and    151.2 mL, respectively, in 
the PP population) after one year of use. Figure 3 
shows the reduction in MBL throughout the treat-
ment period in the ITT population. Most of the 
decrease in MBL was reached after three months 
(weeks 13 – 14) of treatment; it was almost completely 
achieved after nine months (week 38) of treatment and 
remained stable thereafter. 
 Haemoglobin and ferritin levels 
 Table 2 shows the changes in ferritin and haemoglobin 
levels from baseline to the end of the treatment. These 
data, as recorded at each visit, are also represented in 
Figures 4 and 5. 
 Simultaneously to the reduction in MBL, in the ITT 
population, mean ferritin levels increased by 16.0  μ g/L 
in the Levosert  ®  group and by 15.5  μ g/L in the Mirena  ®  
group. A more pronounced increase was observed in 
the PP population (   17.7  μ g/L and    18.2  μ g/L in 
the Levosert  ®  and the Mirena  ®  groups, respectively). 
 Due to the greater availability in iron, haemoglobin 
levels rose in both groups by 0.9 g/dL and by 1.0 g/dL 
in the ITT- and in the PP populations, respectively. 
No statistical differences were observed between the 
two IUSs regarding the increase in ferritin and 
haemoglobin levels ( p   0.1). 
 Endometrial thickness 
 After one year of use, mean endometrial thickness 
was reduced by 7.3 mm in the Levosert  ®  group and 
by 6.9 mm in the Mirena  ®  group, among the ITT 
population. In the PP population, mean endometrial 
thickness was reduced by 7.8 mm and by 7.4 mm 
in the Levosert  ®  - and the Mirena  ®  group, respectively 
(Figure 6). Differences between the two treatments 
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 Figure 2 Randomised controlled trial profi le. 
 Table 1 Baseline characteristics of the intention-to-treat population. 
 Levosert  ®  
(N    142 ) 
 Mirena  ®  
(N    138)  p-value 
Mean age, years (SD) 37.9 (   6.2) 37.7 (   6.1) 0.8018
Mean BMI, kg/m ² (SD) 23.5 (   3.0) 23.9 (   3.0) 0.2485
Mean number of deliveries (SD) 1.9 (   0.7) 1.8 (   0.6) 0.1691
Mean MBL, mL (SD) 180.6 (   81.9) 187.7 (   103.4) 0.5262
Mean haemoglobin level, g/dL (SD) 12.2 (   1.7) 12.2 (   1.5) 0.9182
Mean ferritin level, ng/mL (SD) 21.4 (   23.0) 22.9 (   21.1) 0.5868
Mean endometrial thickness, mm (SD) 11.7 (   4.4) 11.9 (   4.6) 0.6868
Number of subjects suffering from iron defi ciency anaemia 44 37 0.4412
 SD, standard deviation; BMI, body mass index; MBL, menstrual blood loss. 
 Contraception 
 One pregnancy occurred in a woman randomised to 
the Levosert  ®  group after spontaneous expulsion of 
the IUS in the fi rst month after its insertion. 
 Adverse events 
 No deaths occurred during the trial. Four serious 
adverse events (SAEs) unrelated to the study medica-
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 Table 2 Changes from baseline in menstrual blood loss (mL), ferritin ( μ g/L), haemoglobin (g/dL) and endometrial 
thickness (mm) after one year of treatment with Levosert  ®  and Mirena  ®  presented as least-squares mean (see 
Statistical analysis). 
 Levosert  ®  -Mirena  ®  difference 
 Item  Levosert  ®   Mirena  ®   Estimate (95%CI)  p-value 
 Menstrual blood loss (mL) 
ITT population
 Baseline, mean   SD
 End of study, mean   SD
 Change from baseline, least 
squares mean (95%CI)
 180.6    81.9
 35.4    33.6
 142.3
 (135.7  – 148.9)
 187.7    103.4
 34.9    33.5
 146.4
 (139.6  – 153.1)
 4.1 (13.5  – 5.4)  0.3972
PP population
 Baseline, mean   SD
 End of study, mean   SD
 Change from baseline, least 
squares mean (95%CI)
 181.3    81.9
 33.5    27.8
 150.9
 (145.6  – 156.3)
 187.9    102.1
 33.4    30.2
 151.2
 (145.7  – 156.8)
 0.3 (-8.0  – 7.4)  0.9361
 Ferritin level ( m g/L) 
ITT population
 Baseline, mean   SD
 End of study, mean   SD
 Change from baseline, least 
squares mean (95%CI)
 21.4    23.0
 38.5    29.1
 16.0 (12.7  – 19.4)
 22.9    21.1
 38.3    26.1
 15.5 (12.1  – 18.9)
 0.6 (4.2  – 5.3)  0.8203
PP population
 Baseline, mean   SD
 End of study, mean   SD
 Change from baseline, least 
squares mean (95%CI)
 21.8    24.5
 39.8    28.4
 17.7 (14.1  – 21.3)
 22.8    20.2
 41.0    25.9
 18.2 (14.5  – 21.9)
 0.5 (5.7  – 4.7)  0.8547
 Haemoglobin level (g/dL) 
ITT population
 Baseline, mean   SD
 End of study, mean   SD
 Change from baseline, least 
squares mean (95%CI)
 12.2    1.7
 13.3    1.2
 0.9 (0.7  – 1.1)
 12.2    1.5
 13.2    1.4
 0.9 (0.86  – 1.1)
 0.2 (2.9  – 2.4)  0.8668
PP population
 Baseline, mean   SD
 End of study, mean   SD
 Change from baseline, least 
squares mean (95%CI)
 12.3    1.6
 13.3    1.2
 1.0 (0.8  – 1.2)
 12.4    1.4
 13.4    1.2
 1.0 (0.8  – 1.2)
 0.4 (3.3  – 2.5)  0.7972
 Endometrial thickness (mm) 
ITT population
 Baseline, mean   SD
 End of study, mean   SD
 Change from baseline, least 
squares mean (95%CI)
 11.7    4.4
 4.4    2.7
 7.3 (6.8  – 7.8)
 11.9    4.6
 4.8    3.0
 6.9 (6.4  – 7.4)
 0.1 (0.3  – 1.1)  0.2282
PP population
 Baseline, mean   SD
 End of study, mean   SD
 Change from baseline, least 
squares mean (95%CI)
 11.8    4.3
 4.3    2.7
 7.8 (7.3  – 8.3)
 12.2    4.8
 4.5    2.7
 7.4 (6.3  – 8.0)
 0.3 (0.5  – 1.0)  0.4603
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 Figure 5 Increase in haemoglobin level (g/dL) over the 
fi rst treatment year with Levosert  â  and Mirena  â  . ITT, 
intention-to-treat; SEM, standard error of the mean. 
 Figure 3 Decrease in menstrual blood loss (mL) over the 
fi rst treatment year with Levosert  â  and Mirena  â  . ITT, 
intention-to-treat; SEM, standard error of the mean. 
 Figure 4 Increase in ferritin level ( μ g/L) over the fi rst 
treatment year with Levosert  â  and Mirena  â  . ITT, 
intention-to-treat; SEM, standard error of the mean. 
 Figure 6 Decrease in endometrial thickness (mm) over 
the fi rst treatment year with Levosert  â  and Mirena  â  . ITT, 
intention-to-treat; SEM, standard error of the mean. 
herniated disc, headache, pregnancy, and abdominal 
colic). One SAE was considered as possibly related to 
the study medication: a 49-year-old woman developed 
persistent bilateral translucent ovarian follicles (2.5 cm 
in diameter) which were found during an ultrasound 
performed nine months after insertion of Levosert  ®  . 
Histopathological examination of the cysts removed 
by laparoscopy confi rmed their benignity. The subject 
completely recovered and participated in the trial until 
the end. Overall, the incidence of ovarian cysts was 
10% and 15.2% in the Levosert  ®  group and in the 
Mirena  ®  group, respectively. 
 Fifteen subjects discontinued participation in the 
study due to an adverse event (AE). Among them, six 
women in the Levosert  ®  group and fi ve in the Mirena  ®  
group spontaneously expelled the device. One woman 
in the Levosert  ®  group left the study because of amen-
orrhoea and three others in the Mirena  ®  group did so 
for arterial hypertension, ovarian cyst, and pelvic pain, 
respectively. No uterine perforation was observed in 
either group. Table 3 displays the treatment-related AEs 
reported by at least 5% of the women in each group. 
All those pertaining to Levosert  ®  were anticipated as 
they have been described in association with the use 
of Mirena  ®  . AEs were reported almost with the same 
frequency in both groups. The adverse event most fre-
quently mentioned was a  ‘ prolonged menstrual cycle ’ . 




























































Impact of Levosert® on heavy menstrual bleeding Mawet et al.
The European Journal of Contraception and Reproductive Health Care 9
absence of menses during    90 days) was only half 
that of prolonged menstrual cycle, and was comparable 
in both groups. Patients may consider absence of 
menstrual or withdrawal bleeding as an additional 
benefi t rather than a nuisance, depending on societal 
and cultural views. The incidence of spotting was high 
during the fi rst three months following insertion of 
the IUSs but decreased dramatically thereafter. Simi-
larly, HMB was still observed in the beginning of the 
study but tended to disappear after two months of 
treatment. Users complained of pain after insertion of 
the IUS with the same frequency in both Levosert  ®  
and Mirena  ®  groups (7.1% and 6.5%, respectively). 
 D I S C U S S I O N  
 Findings and interpretation 
 In this trial, the reference product Mirena  ®  was com-
pared to a new LNG-IUS called Levosert  ®  that releases 
daily a similar amount of LNG. Both treatment modal-
ities reduced MBL to the same extent (Levosert  ®  : by 
79.0%    18.2%; Mirena  ®  : by 79.2%    19.8%). Serial 
TVUSs confi rmed that both IUSs caused a compa-
rable, dramatic thinning of the endometrium, as early 
as three months after the initiation of treatment (Fig-
ure 6), confi rming the previously documented endo-
metrial atrophy caused by locally applied LNG 20 . The 
important decrease in endometrial thickness between 
the screening period and the insertion of the IUS 
results from the fact that, at screening, that thickness 
was measured during the secretory phase of a sponta-
neous ovulatory cycle while, at IUS insertion, it was 
measured during the menstrual period. 
 The haemoglobin concentration and the plasma 
levels of ferritin increased progressively as MBL dimin-
ished. There were no statistical differences observed 
between the two groups. 
 One pregnancy occurred during the trial in a 
woman included in the Levosert  ®  group, after expul-
sion of the device, probably during the preceding 
menses. Seven and eight women in the Levosert  ®  and 
Mirena ®  groups, respectively, prematurely discontin-
ued their partaking in the study because of adverse 
reactions. The incidence of drug-related adverse events 
was similar in both groups (Table 3) and is in line with 
previous studies conducted with Mirena  ®  for contra-
ception or HMB indications. The expulsion rates were 
4.2% and 3.6% in the Levosert  ®  and the Mirena  ®  
 Table 3 Drug-related adverse events occurring in at least 
5% of the women of each treatment group. 
 Adverse events 
 Levosert  ®  
(N    141) 
 n (%) 
 Mirena  ®  
(N    139) 
 n (%) 
Prolonged menstrual 
cycle
44 (31) 49 (35)
Spotting between 
menses
41 (29) 50 (36)
Amenorrhoea 21 (15) 24 (17)
Ovarian cyst 14 (10) 21 (15)
Breast tension 6 (4) 11 (8)
Heavy menstrual 
bleeding
11 (8) 8 (6)
Pain after IUS Insertion 10 (7) 9 (6)
 IUS, intrauterine system. 
groups, respectively, a lower incidence than that 
reported in the Mirena  ®  HMB studies. Kaunitz  et  al ., 
in their pivotal paper, mentioned a 4.5% expulsion rate 
while Xiao  et  al ., Kriplani  et  al . and Shaw  et  al ., in their 
limited series on Mirena  ®  , reported even higher and 
 – to many practitioners used to inserting intrauterine 
contraceptives  – surprising expulsion rates of 12%, 
9.5% and 6%, respectively 12,21 – 23 . Overall, both 
treatments were well tolerated. There were no differ-
ences between the two IUSs with respect to the pain 
experienced by the women during or after insertion. 
 Strengths and weaknesses of the study 
 This study demonstrates that both IUSs have similar 
safety and effi cacy profi les when used for the treat-
ment of HMB. One limitation of our trial, due to 
the distinct IUS aspects and insertion techniques, was 
its single-blind nature (i.e., the gynaecologist knew 
which IUS was inserted whereas the woman did not). 
This could have infl uenced the perception of the 
specialist regarding the effi cacy and/or the safety 
profi le of the treatments and possibly have biased the 
results. Therefore, an objective criterion independent 
of the investigator ’ s opinion (reduction of MBL) was 
selected as the primary endpoint. The effi cacy of Levo-
sert  ®  in that respect was also compared with that of 
Mirena  ®  by measuring their impact on plasma ferritin 
and on haemoglobin. The possible subjective opinion 
of the investigators could not have had any bearing 
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parameters. The similarity of the data pertaining to 
both groups supports the equivalence of the two 
treatment modalities and indicates that single blinding 
likely had no infl uence on the results. 
 Differences in results and conclusions 
in relation to other studies 
 The reduction in MBL achieved by the LNG-IUS 
differs greatly between studies, with results ranging 
from 50 to 85% after six months of treatment 24 – 26 and 
from 69 to 95% after one year 25,27 – 31 . These differences 
are probably the consequence of the heterogeneity of 
the underlying causes of HMB. In this study, we there-
fore excluded all women with structural endometrial 
or uterine abnormalities. 
 Relevance of the fi ndings: Implications 
for clinicians 
 Recurrent HMB may result in iron defi ciency and 
anaemia 32 , classically defi ned by a haemoglobin 
level    12.0 g/dL associated with a ferritin level    15 
ng/mL. This condition may lead to lasting fatigue, 
palpitations and malaise which interfere with daily 
activities. As observed in other LNG-IUS trials 8,32 , 
more than 25% women allocated to both groups suf-
fered at baseline from iron defi ciency anaemia. Given 
the prevalence of anaemia, it is crucial to assess the 
changes in haemoglobin and ferritin levels when treat-
ing HMB. The favourable effects of the LNG-IUS on 
haemoglobin and ferritin levels were fi rst reported in 
1982 by Heikkila  et  al . 33 and they have been con-
fi rmed by many other investigators 21,27,29,30,33,34 . In 
this trial, the haemoglobin and ferritin levels rose 
steadily and had not reached a plateau after 52 weeks 
of treatment indicating the very progressive correc-
tion of the iron defi ciency anaemia. These data sug-
gest that iron supplementation may be benefi cial in 
addition to the LNG-IUS. Concomitant iron sup-
plementation was allowed during the course of the 
study but was taken by a very limited and similar 
proportion of subjects in both groups (three and one 
subjects in the Levosert  ®  and the Mirena  ®  groups, 
respectively). 
 Unanswered questions and future research 
 As detailed in Contraceptive Technology Update 
dated September 2013, the contraceptive effi cacy of 
Levosert  ®  is presently being assessed in a large US 
clinical trial conducted by Medicines 360, a San Fran-
cisco-based non-profi t pharmaceutical company, with 
an eye to making LNG-IUS available at a low price 
to public sector clinics 35 . 
 C O N C L U S I O N  
 The new IUS releasing controlled amounts of LNG, 
Levosert  ®  , is equally effi cacious during the fi rst year 
of use as the reference product Mirena  ®  for treating 
HMB. Both IUSs have similar safety profi les and are 
commensurately well-tolerated. 
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